Antioxidant approaches for the treatment of Alzheimer’s disease
暂无分享,去创建一个
Hyoung-Gon Lee | Xiongwei Zhu | G. Casadesus | A. Nunomura | R. Castellani | Mark A. Smith | George Perry | Hyun Pil Lee
[1] J. Paskavitz,et al. Efficacy of a Vitamin/Nutriceutical Formulation for Early-stage Alzheimer's Disease: A 1-year, Open-label Pilot Study With an 16-Month Caregiver Extension , 2009, American journal of Alzheimer's disease and other dementias.
[2] Eric Klann,et al. Overexpression of SOD-2 reduces hippocampal superoxide and prevents memory deficits in a mouse model of Alzheimer's disease , 2009, Proceedings of the National Academy of Sciences.
[3] Xiongwei Zhu,et al. Amyloid-β overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins , 2008, Proceedings of the National Academy of Sciences.
[4] Lewis H Kuller,et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. , 2008, JAMA.
[5] G. McKhann,et al. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease , 2008, Nature Medicine.
[6] Xiongwei Zhu,et al. Dynamin-like protein 1 reduction underlies mitochondrial morphology and distribution abnormalities in fibroblasts from sporadic Alzheimer's disease patients. , 2008, The American journal of pathology.
[7] M. Sano,et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study , 2008, The Lancet.
[8] P. Crane,et al. Antioxidant Vitamin Supplement Use and Risk of Dementia or Alzheimer's Disease in Older Adults , 2008, Journal of the American Geriatrics Society.
[9] M. Beal,et al. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. , 2008, Trends in molecular medicine.
[10] G. Perry,et al. Lipid peroxidation and 4-hydroxy-2-nonenal formation by copper ion bound to amyloid-β peptide , 2007 .
[11] G. Perry,et al. Three histidine residues of amyloid-beta peptide control the redox activity of copper and iron. , 2007, Biochemistry.
[12] P. Singal,et al. Role of Advanced Glycation End Products in Hypertension and Atherosclerosis: Therapeutic Implications , 2007, Cell Biochemistry and Biophysics.
[13] A. Nunomura,et al. Autophagocytosis of mitochondria is prominent in Alzheimer disease , 2007, Journal of the Neurological Sciences.
[14] J. Trnka,et al. Mitochondrial targeting of quinones: therapeutic implications. , 2007, Mitochondrion.
[15] George Perry,et al. Alzheimer disease, the two-hit hypothesis: an update. , 2007, Biochimica et biophysica acta.
[16] Robin A. J. Smith,et al. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. , 2007, Annual review of pharmacology and toxicology.
[17] Mark A. Smith,et al. Nanoparticle iron chelators: A new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance , 2006, Neuroscience Letters.
[18] N. Vaziri,et al. Mechanisms of Disease: oxidative stress and inflammation in the pathogenesis of hypertension , 2006, Nature Clinical Practice Nephrology.
[19] A D Roses,et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease , 2006, The Pharmacogenomics Journal.
[20] J. Simard,et al. Recommendations of the National Heart, Lung, and Blood Institute Working Group on Cerebrovascular Biology and Disease , 2006, Stroke.
[21] J. Quinn,et al. Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. , 2006, Human molecular genetics.
[22] Hyoung-Gon Lee,et al. Neuropathology of Alzheimer disease: pathognomonic but not pathogenic , 2006, Acta Neuropathologica.
[23] P. Reddy,et al. Mitochondrial Oxidative Damage in Aging and Alzheimer's Disease: Implications for Mitochondrially Targeted Antioxidant Therapeutics , 2006, Journal of biomedicine & biotechnology.
[24] B. Strooper,et al. Presenilin clinical mutations can affect γ‐secretase activity by different mechanisms , 2006, Journal of neurochemistry.
[25] M. W. Anders,et al. Targeting antioxidants to mitochondria: a new therapeutic direction. , 2006, Biochimica et biophysica acta.
[26] Hyoung-Gon Lee,et al. Amyloid beta: the alternate hypothesis. , 2006, Current Alzheimer research.
[27] M. Beal,et al. Are mitochondria critical in the pathogenesis of Alzheimer's disease? , 2005, Brain Research Reviews.
[28] Robin A. J. Smith,et al. Synthesis and Characterization of a Triphenylphosphonium-conjugated Peroxidase Mimetic , 2005, Journal of Biological Chemistry.
[29] D. Bennett,et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. , 2005, The New England journal of medicine.
[30] A. M. James,et al. Interactions of Mitochondria-targeted and Untargeted Ubiquinones with the Mitochondrial Respiratory Chain and Reactive Oxygen Species , 2005, Journal of Biological Chemistry.
[31] Hyoung-Gon Lee,et al. Tau phosphorylation in Alzheimer's disease: pathogen or protector? , 2005, Trends in molecular medicine.
[32] R. Touyz. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance? , 2004, Hypertension.
[33] E. Schiffrin,et al. Reactive oxygen species in vascular biology: implications in hypertension , 2004, Histochemistry and Cell Biology.
[34] H. Szeto,et al. Cell-permeable Peptide Antioxidants Targeted to Inner Mitochondrial Membrane inhibit Mitochondrial Swelling, Oxidative Cell Death, and Reperfusion Injury* , 2004, Journal of Biological Chemistry.
[35] M. Mattson. Pathways towards and away from Alzheimer's disease , 2004, Nature.
[36] Eric J Topol,et al. Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins , 2004, The Lancet.
[37] A. Mooradian,et al. Recent trials of antioxidant therapy: what should we be telling our patients? , 2004, Cleveland Clinic journal of medicine.
[38] Xiongwei Zhu,et al. Alzheimer's disease: the two-hit hypothesis , 2004, The Lancet Neurology.
[39] J. Trojanowski,et al. Early Vitamin E supplementation in young but not aged mice reduces Aβ levels and amyloid deposition in a transgenic model of Alzheimer's disease , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[40] E. R. Taylor,et al. Superoxide Activates Uncoupling Proteins by Generating Carbon-centered Radicals and Initiating Lipid Peroxidation , 2003, Journal of Biological Chemistry.
[41] S. O. Bachurin,et al. Comparative Study of Action Mechanisms of Dimebon and Memantine on AMPA- and NMDA-Subtypes Glutamate Receptors in Rat Cerebral Neurons , 2003, Bulletin of Experimental Biology and Medicine.
[42] G. Oxenkrug,et al. Mitochondria as a Target for Neurotoxins and Neuroprotective Agents , 2003, Annals of the New York Academy of Sciences.
[43] Xiongwei Zhu,et al. Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's and other neurodegenerative diseases? , 2002, Free radical biology & medicine.
[44] George Perry,et al. Role of mitochondrial dysfunction in Alzheimer's disease , 2002, Journal of neuroscience research.
[45] J. Joseph,et al. Amyloid-β and τ serve antioxidant functions in the aging and Alzheimer brain , 2002 .
[46] J. Witteman,et al. Dietary intake of antioxidants and risk of Alzheimer disease. , 2002, JAMA.
[47] Xiongwei Zhu,et al. Differential activation of neuronal ERK, JNK/SAPK and p38 in Alzheimer disease: the ‘two hit’ hypothesis , 2001, Mechanisms of Ageing and Development.
[48] S. Bachurin,et al. Dimebon and Tacrine Inhibit Neurotoxic Action of β-Amyloid in Culture and Block L-type Ca2+ Channels , 2001, Bulletin of Experimental Biology and Medicine.
[49] A. Nunomura,et al. Oxidative Damage Is the Earliest Event in Alzheimer Disease , 2001, Journal of neuropathology and experimental neurology.
[50] C. Masters,et al. Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits β-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice , 2001, Neuron.
[51] E. Giacobini. Cholinesterase Inhibitors Stabilize Alzheimer's Disease , 2000, Annals of the New York Academy of Sciences.
[52] S. Melov,et al. Extension of life-span with superoxide dismutase/catalase mimetics. , 2000, Science.
[53] J B Schulz,et al. Glutathione, oxidative stress and neurodegeneration. , 2000, European journal of biochemistry.
[54] N. Vaziri,et al. Induction of oxidative stress by glutathione depletion causes severe hypertension in normal rats. , 2000, Hypertension.
[55] A. Nunomura,et al. Mitochondrial abnormalities in Alzheimer disease , 2000, Neurobiology of Aging.
[56] Mark A. Smith,et al. In Situ Oxidative Catalysis by Neurofibrillary Tangles and Senile Plaques in Alzheimer’s Disease , 2000, Journal of neurochemistry.
[57] R. L. Russell,et al. Increased neuronal glucose-6-phosphate dehydrogenase and sulfhydryl levels indicate reductive compensation to oxidative stress in Alzheimer disease. , 1999, Archives of biochemistry and biophysics.
[58] S. Cuzzocrea,et al. A nonpeptidyl mimic of superoxide dismutase with therapeutic activity in rats. , 1999, Science.
[59] Xudong Huang,et al. The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. , 1999, Biochemistry.
[60] George Perry,et al. RNA Oxidation Is a Prominent Feature of Vulnerable Neurons in Alzheimer’s Disease , 1999, The Journal of Neuroscience.
[61] D. Tribble. Antioxidant Consumption and Risk of Coronary Heart Disease: Emphasis on Vitamin C, Vitamin E, and β-Carotene A Statement for Healthcare Professionals From the American Heart Association , 1999 .
[62] S. Bondy,et al. Promotion of transition metal-induced reactive oxygen species formation by β-amyloid , 1998, Brain Research.
[63] G. Perry,et al. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[64] K. Gulya,et al. The cholinergic system in Alzheimer's disease , 1997, Progress in Neurobiology.
[65] P Woodbury,et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. , 1997, The New England journal of medicine.
[66] D. Selkoe,et al. Alzheimer's Disease--Genotypes, Phenotype, and Treatments , 1997, Science.
[67] M. Mattson,et al. Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors , 1996, Nature Medicine.
[68] W. Danysz,et al. The effects of mitochondrial failure upon cholinergic toxicity in the nucleus basalis. , 1996, Neuroreport.
[69] W. Danysz,et al. Infusion of (+) -MK-801 and memantine -- contrasting effects on radial maze learning in rats with entorhinal cortex lesion. , 1996, European journal of pharmacology.
[70] C. Parsons,et al. Learning deficits induced by chronic intraventricular infusion of quinolinic acid--protection by MK-801 and memantine. , 1996, European journal of pharmacology.
[71] Mark A. Smith,et al. Radical AGEing in Alzheimer's disease , 1995, Trends in Neurosciences.
[72] P. Jenner. Oxidative damage in neurodegenerative disease , 1994, The Lancet.
[73] B. Hyman,et al. Functional Alterations in Alzheimer's Disease: Selective Loss of Mitochondrial-encoded Cytochrome Oxidase mRNA in the Hippocampal Formation , 1994, Journal of neuropathology and experimental neurology.
[74] C. Parsons,et al. Patch clamp studies on the kinetics and selectivity of N-methyl-d-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan) , 1993, Neuropharmacology.
[75] D. McLachlan,et al. Desferrioxamine and Alzheimer's Disease: Video Home Behavior Assessment of Clinical Course and Measures of Brain Aluminum , 1993, Therapeutic drug monitoring.
[76] S. Kish,et al. Brain α‐Ketoglutarate Dehydrotenase Complex Activity in Alzheimer's Disease , 1993 .
[77] P. Whitehouse. Cholinergic therapy in dementia , 1993, Acta neurologica Scandinavica. Supplementum.
[78] A. Shetter,et al. Cortical biopsy in Alzheimer's disease: Diagnostic accuracy and neurochemical, neuropathological, and cognitive correlations , 1992 .
[79] J. Hardy,et al. Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.
[80] C. Miller,et al. Alzheimer's and Parkinson's disease. Brain levels of glutathione, glutathione disulfide, and vitamin E. , 1991, Molecular and chemical neuropathology.
[81] D. McLachlan,et al. Intramuscular desferrioxamine in patients with Alzheimer's disease , 1991, The Lancet.
[82] C. Yates,et al. Enzyme Activities in Relation to pH and Lactate in Postmortem Brain in Alzheimer‐Type and Other Dementias , 1990, Journal of neurochemistry.
[83] D. Neary,et al. Presynaptic Cholinergic Dysfunction in Patients with Dementia , 1983, Journal of neurochemistry.
[84] D. Harman,et al. Free Radical Theory of Aging: Inhibition of Amyloidosis in Mice by Antioxidants; Possible Mechanism * , 1976, Journal of the American Geriatrics Society.
[85] D. Harman. Aging: a theory based on free radical and radiation chemistry. , 1956, Journal of gerontology.
[86] D. Selkoe. Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.
[87] Mark A. Smith,et al. Nanoparticle and iron chelators as a potential novel Alzheimer therapy. , 2010, Methods in molecular biology.
[88] R. Castellani,et al. Alzheimer disease. , 2010, Disease-a-month : DM.
[89] J. Hardy,et al. The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .
[90] J. Wesson Ashford,et al. APOE genotype effects on alzheimer’s disease onset and epidemiology , 2007, Journal of Molecular Neuroscience.
[91] B. Teter,et al. ApoE-dependent plasticity in Alzheimer’s disease , 2007, Journal of Molecular Neuroscience.
[92] E. Giacobini. Long-term stabilizing effect of cholinesterase inhibitors in the therapy of Alzheimer' disease. , 2002, Journal of neural transmission. Supplementum.
[93] J. Joseph,et al. Amyloid-beta and tau serve antioxidant functions in the aging and Alzheimer brain. , 2002, Free radical biology & medicine.
[94] E. Giacobini. Do Cholinesterase Inhibitors Have Disease-Modifying Effects in Alzheimer’s Disease? , 2001, CNS drugs.
[95] D. Selkoe. Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. , 2001, Journal of Alzheimer's disease : JAD.
[96] R. Castellani,et al. Reactive Oxygen Species Mediate Cellular Damage in Alzheimer Disease. , 1998, Journal of Alzheimer's disease : JAD.
[97] D. Selkoe. Alzheimer's disease: genotypes, phenotypes, and treatments. , 1997, Science.
[98] J. Lohr,et al. Free radical involvement in neuropsychiatric illnesses. , 1995, Psychopharmacology bulletin.
[99] Brown Ja,et al. Free radical involvement in neuropsychiatric illnesses. , 1995 .
[100] D. Bennett,et al. Dietary Intake of Antioxidant Nutrients and the Risk of Incident Alzheimer Disease in a Biracial Community Study , 2022 .